Editas Medicine (EDIT) Free Cash Flow (2015 - 2025)
Editas Medicine (EDIT) reported Free Cash Flow of -$30.7 million for Q3 2025, up 44.64% year-over-year from -$21.2 million in Q3 2024, and up 38.8% quarter-over-quarter from -$50.2 million in Q2 2025.
Editas Medicine (EDIT) Free Cash Flow (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of Free Cash Flow data on file, last reported at -$30.7 million in Q3 2025.
- Free Cash Flow for Q3 2025 came in at -$30.7 million, up 44.64% year-over-year; the trailing twelve-month figure through Dec 2025 was -$128.9 million (up 38.74% YoY), and the FY2024 annual result was -$210.3 million, down 58.13% from the prior year.
- Free Cash Flow improved to -$30.7 million in Q3 2025 per EDIT's latest filing, from -$50.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$19.7 million in Q4 2023 and troughed at -$60.6 million in Q2 2024.
- A 5-year average of -$43.1 million and a median of -$42.5 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow jumped 54.14% in 2023, then tumbled 116.24% in 2024.
- A 5-year view of Free Cash Flow shows it stood at -$34.7 million in 2021, then fell by 23.5% to -$42.9 million in 2022, then jumped by 54.14% to -$19.7 million in 2023, then plunged by 116.24% to -$42.5 million in 2024, then gained by 27.77% to -$30.7 million in 2025.
- Business Quant data shows EDIT's Free Cash Flow at -$30.7 million in Q3 2025, -$50.2 million in Q2 2025, and -$47.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -30.73 Mn |
| Sep 30, 2025 | -30.73 Mn |
| Jun 30, 2025 | -50.21 Mn |
| Jun 30, 2025 | -50.21 Mn |
| Mar 31, 2025 | -47.91 Mn |
| Mar 31, 2025 | -47.91 Mn |
| Dec 31, 2024 | -42.54 Mn |
| Dec 31, 2024 | -42.54 Mn |
| Sep 30, 2024 | -55.51 Mn |
| Sep 30, 2024 | -55.51 Mn |
| Jun 30, 2024 | -60.56 Mn |
| Jun 30, 2024 | -60.56 Mn |
| Mar 31, 2024 | -51.74 Mn |
| Mar 31, 2024 | -51.74 Mn |
| Dec 31, 2023 | -19.67 Mn |
| Dec 31, 2023 | -19.67 Mn |
| Sep 30, 2023 | -38.66 Mn |
| Sep 30, 2023 | -38.66 Mn |
| Jun 30, 2023 | -37.08 Mn |
| Jun 30, 2023 | -37.08 Mn |